Rate Video

ESMO 2022 | Unmet needs in desmoid tumors

Robin Jones • 1 Nov 2022

Robin Jones, MBBS, MRCP, MD, The Royal Marsden NHS Foundation Trust, London, UK, discusses unmet needs in the treatment of desmoid tumors and how the Phase II/III RINGSIDE trial (NCT04871282) could introduce a new treatment option for these patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Late-stage trials in rare sarcoma subtypes

Robin Jones • 15 Jun 2021

INVICTUS and INTRIGUE: investigating ripretinib in patients with advanced GIST

Robin Jones • 13 Apr 2022

APROMISS: anlotinib versus dacarbazine in advanced synovial sarcoma.

Robin Jones • 15 Jun 2021

Challenges of desmoid tumors

Robin Jones • 1 Nov 2022

Related Videos

Trabectedin and pazopanib: an indirect comparison of their ability to treat LMS

How has the trabectedin extended access program benefited sarcoma patients?

The current state of drug development against sarcomas

Response rates to immunotherapy in sarcoma patients and implications for future therapies

Gary Schwartz • 3 Jun 2016